Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis Unveils Path to Becoming a Top 5 US Player by 2027
BioSpace
Thu, 09/22/22 - 11:17 pm
Tags:
Novartis
Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court
Fierce Pharma
Wed, 09/21/22 - 08:02 pm
Tags:
Novartis, Supreme Court, Gilenya, patents, legal, MS
Unsealed documents detail Biogen's fight against Sandoz Tysabri biosimilar
Endpoints
Tue, 09/20/22 - 08:36 pm
Tags:
Biogen, Novartis, Sandoz, biosimilars, Tysabri, MS, multiple sclerosis
Sandoz reports data from Phase I/III trial of denosumab for osteoporosis
Clinical Trials Arena
Tue, 09/20/22 - 10:07 am
Tags:
Novartis, Sandoz, clinical trials, biosimilarts, denosumab, osteoporosis
Novartis investing US$300m in next generation biotherapeutics development
Biopharma Reporter
Mon, 09/19/22 - 09:14 am
Tags:
Novartis, biologics, biotherapeutics, drug development
Novartis headquarters raided in Swiss competition authority's patent probe
Fierce Pharma
Thu, 09/15/22 - 10:54 am
Tags:
Novartis, Switzerland, patents, competition
Novartis dodges Gilenya kickback claims—again—after whistleblower lawsuit dismissed
Fierce Pharma
Wed, 09/14/22 - 08:04 pm
Tags:
Novartis, whistleblowers, whistleblower lawsuit, Gilenya, kickbacks, MS
Novartis touts Cosentyx win in debilitating skin condition. Can it challenge AbbVie's Humira?
Fierce Pharma
Tue, 09/13/22 - 08:03 pm
Tags:
Novartis, FDA, Cosentyx, AbbVie, Humira, hidradenitis suppurativa
Novartis funnels $300M into early biologic drug manufacturing
BioPharma Dive
Mon, 09/12/22 - 11:36 pm
Tags:
Novartis, biologics, drug manufacturing, Slovenia, Austria
ESMO 2022 – the new liver cancer entrants line up
EP Vantage
Thu, 09/8/22 - 10:39 am
Tags:
ESMO, liver cancer, Keytruda, tislelizumab, camrelizumab, Merck, BeiGene, Novartis
Novartis' Entresto infringes on university patents, lawsuit claims
Endpoints
Wed, 08/31/22 - 10:29 am
Tags:
Novartis, Entresto, legal, patents
Backed by Medicxi, Novartis vets launch rare blood disorder biotech with fresh take on drug class used in cancers
Endpoints
Sun, 08/28/22 - 10:10 pm
Tags:
Novartis, AKT inhibitors, Vaderis Therapeutics, Medicxi
Novartis cuts manufacturing jobs, closes North Carolina plant ahead of Sandoz spinoff
Fierce Pharma
Fri, 08/26/22 - 10:45 am
Tags:
Novartis, drug manufacturing, Sandoz, generics
Revealed: which pharma companies leading the way in artificial intelligence
Clinical Trials Arena
Fri, 08/26/22 - 10:37 am
Tags:
artificial intelligence, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Takeda, GSK, Bayer, Astellas
It's a spinoff: Novartis parts ways with Sandoz just as its generics biz shows signs of recovery
Fierce Pharma
Thu, 08/25/22 - 11:30 am
Tags:
spinoffs, Novartis, Sandoz, generics
Safety worries spur Novartis to suspend drug dosing in Huntington’s trial
BioPharma Dive
Thu, 08/25/22 - 11:29 am
Tags:
Novartis, Huntington's disease, clinical trials, branaplam
Merck backs radiopharmaceutical startup Aktis, joining other high-profile backers
BioPharma Dive
Thu, 08/25/22 - 10:55 am
Tags:
Aktis Oncology, radiopharmaceuticals, Merck, Novartis, Bristol Myers Squibb
Third Harmonic, with an old Novartis drug in hand, braves frosty IPO waters in a quick-fire cash grab
Fierce Biotech
Wed, 08/24/22 - 10:40 pm
Tags:
Third Harmonic Bio, IPOs, Novartis, allergies, inflammatory diseases
Vaderis Forms to Tackle Vascular Malformations with Novartis Vet at the Helm
BioSpace
Mon, 08/22/22 - 10:24 am
Tags:
Vaderis, Novartis, vascular malformations, clinical trials, VAD044
Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment
Fierce Biotech
Fri, 08/19/22 - 10:47 am
Tags:
Novartis, Gilenya, kidney disease, chronic kidney disease

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.